Successful mycophenolate mofetil treatment of glomerular disease

William A. Briggs, Michael J Choi, Paul J. Scheel

Research output: Contribution to journalArticle

Abstract

Eight patients with resistant and/or relapsing nephrotic syndrome or renal insufficiency were empirically treated with mycophenolate mofetil (MMF). The underlying glomerular diseases were membranous nephropathy (N = 3), minimal change disease (n = 2), focal segmental glomerulosclerosis (n = 1), and lupus nephritis (N = 2). Treatment with MMF 0.75 to 1.0 g twice daily, either as monotherapy or in combination with low-doses steroid treatment, resulted in substantial reductions in proteinuria or stabilization of serum creatinine. In relapsing patients following withdrawal from cyclosporin A, MMF achieved suppression of proteinuria equivalent to or better than that which occurred during cyclosporin A treatment. Steroids were successfully withdrawn in each of the non-lupus patients. MMF was well tolerated with no evidence of hematologic, hepatic, or other toxicity. These clinical anecdotes demonstrate the short-term clinical efficacy of MMF treatment. In addition, they suggest that MMF may have major steroid-sparing effects and might represent an alternative to cyclosporin A in appropriate patients.

Original languageEnglish (US)
JournalAmerican Journal of Kidney Diseases
Volume31
Issue number2
StatePublished - Feb 1998

Fingerprint

Mycophenolic Acid
Cyclosporine
Steroids
Proteinuria
Therapeutics
Anecdotes
Lipoid Nephrosis
Membranous Glomerulonephritis
Lupus Nephritis
Nephrotic Syndrome
Renal Insufficiency
Creatinine
Liver
Serum

Keywords

  • Glomerular disease
  • Mycophenolate mofetil
  • Nephrotic syndrome

ASJC Scopus subject areas

  • Nephrology

Cite this

Successful mycophenolate mofetil treatment of glomerular disease. / Briggs, William A.; Choi, Michael J; Scheel, Paul J.

In: American Journal of Kidney Diseases, Vol. 31, No. 2, 02.1998.

Research output: Contribution to journalArticle

Briggs, William A. ; Choi, Michael J ; Scheel, Paul J. / Successful mycophenolate mofetil treatment of glomerular disease. In: American Journal of Kidney Diseases. 1998 ; Vol. 31, No. 2.
@article{ad23d2aebf0a436fba19b788219d68c4,
title = "Successful mycophenolate mofetil treatment of glomerular disease",
abstract = "Eight patients with resistant and/or relapsing nephrotic syndrome or renal insufficiency were empirically treated with mycophenolate mofetil (MMF). The underlying glomerular diseases were membranous nephropathy (N = 3), minimal change disease (n = 2), focal segmental glomerulosclerosis (n = 1), and lupus nephritis (N = 2). Treatment with MMF 0.75 to 1.0 g twice daily, either as monotherapy or in combination with low-doses steroid treatment, resulted in substantial reductions in proteinuria or stabilization of serum creatinine. In relapsing patients following withdrawal from cyclosporin A, MMF achieved suppression of proteinuria equivalent to or better than that which occurred during cyclosporin A treatment. Steroids were successfully withdrawn in each of the non-lupus patients. MMF was well tolerated with no evidence of hematologic, hepatic, or other toxicity. These clinical anecdotes demonstrate the short-term clinical efficacy of MMF treatment. In addition, they suggest that MMF may have major steroid-sparing effects and might represent an alternative to cyclosporin A in appropriate patients.",
keywords = "Glomerular disease, Mycophenolate mofetil, Nephrotic syndrome",
author = "Briggs, {William A.} and Choi, {Michael J} and Scheel, {Paul J.}",
year = "1998",
month = "2",
language = "English (US)",
volume = "31",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Successful mycophenolate mofetil treatment of glomerular disease

AU - Briggs, William A.

AU - Choi, Michael J

AU - Scheel, Paul J.

PY - 1998/2

Y1 - 1998/2

N2 - Eight patients with resistant and/or relapsing nephrotic syndrome or renal insufficiency were empirically treated with mycophenolate mofetil (MMF). The underlying glomerular diseases were membranous nephropathy (N = 3), minimal change disease (n = 2), focal segmental glomerulosclerosis (n = 1), and lupus nephritis (N = 2). Treatment with MMF 0.75 to 1.0 g twice daily, either as monotherapy or in combination with low-doses steroid treatment, resulted in substantial reductions in proteinuria or stabilization of serum creatinine. In relapsing patients following withdrawal from cyclosporin A, MMF achieved suppression of proteinuria equivalent to or better than that which occurred during cyclosporin A treatment. Steroids were successfully withdrawn in each of the non-lupus patients. MMF was well tolerated with no evidence of hematologic, hepatic, or other toxicity. These clinical anecdotes demonstrate the short-term clinical efficacy of MMF treatment. In addition, they suggest that MMF may have major steroid-sparing effects and might represent an alternative to cyclosporin A in appropriate patients.

AB - Eight patients with resistant and/or relapsing nephrotic syndrome or renal insufficiency were empirically treated with mycophenolate mofetil (MMF). The underlying glomerular diseases were membranous nephropathy (N = 3), minimal change disease (n = 2), focal segmental glomerulosclerosis (n = 1), and lupus nephritis (N = 2). Treatment with MMF 0.75 to 1.0 g twice daily, either as monotherapy or in combination with low-doses steroid treatment, resulted in substantial reductions in proteinuria or stabilization of serum creatinine. In relapsing patients following withdrawal from cyclosporin A, MMF achieved suppression of proteinuria equivalent to or better than that which occurred during cyclosporin A treatment. Steroids were successfully withdrawn in each of the non-lupus patients. MMF was well tolerated with no evidence of hematologic, hepatic, or other toxicity. These clinical anecdotes demonstrate the short-term clinical efficacy of MMF treatment. In addition, they suggest that MMF may have major steroid-sparing effects and might represent an alternative to cyclosporin A in appropriate patients.

KW - Glomerular disease

KW - Mycophenolate mofetil

KW - Nephrotic syndrome

UR - http://www.scopus.com/inward/record.url?scp=17344373954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344373954&partnerID=8YFLogxK

M3 - Article

C2 - 9469489

AN - SCOPUS:17344373954

VL - 31

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 2

ER -